Literature DB >> 754367

Sicca complex and cholestatic jaundice in two members of a family caused by thiabendazole.

A I Fink, C J MacKay, S S Cutler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 754367      PMCID： PMC1311616     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN： 0065-9533


× No keyword cloud information.
  12 in total

1.  Scleroderma, Sjögren-like syndrome, and chronic graft-versus-host disease.

Authors:  T J Lawley; G L Peck; H M Moutsopoulos; A A Gratwohl; A B Deisseroth
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

2.  Sjögren-type syndrome after allogeneic bone-marrow transplantation.

Authors:  A A Gratwohl; A A Gratwhol; H M Moutsopoulos; T M Chused; M Akizuki; R O Wolf; J B Sweet; A B Deisseroth
Journal:  Ann Intern Med       Date:  1977-12       Impact factor: 25.391

3.  Liver disease in Sjögren's syndrome and rheumatoid arthritis.

Authors:  K Whaley; R B Goudie; J Williamson; G Nuki; W C Dick; W W Buchanan
Journal:  Lancet       Date:  1970-04-25       Impact factor: 79.321

Review 4.  A unified concept of autoimmune hepatitis.

Authors:  D Doniach; J G Walker
Journal:  Lancet       Date:  1969-04-19       Impact factor: 79.321

5.  The mucin-deficient dry eye.

Authors:  M A Lemp
Journal:  Int Ophthalmol Clin       Date:  1973

6.  Severe intrahepatic cholestasis due to thiabendazole.

Authors:  R Jalota; J W Freston
Journal:  Am J Trop Med Hyg       Date:  1974-07       Impact factor: 2.345

7.  Chromomycosis. Treatment with thiabendazole.

Authors:  M A Bayles
Journal:  Arch Dermatol       Date:  1971-11

8.  Thiabendazole therapy in human trichinellosis.

Authors:  Z Kozar; J Jackowska-Klimowicz; E Sladki
Journal:  Wiad Parazytol       Date:  1966

9.  "Sicca complex" in liver disease.

Authors:  P L Golding; R Bown; A M Mason; E Taylor
Journal:  Br Med J       Date:  1970-11-07

Review 10.  Tear physiology and dry eyes.

Authors:  F J Holly; M A Lemp
Journal:  Surv Ophthalmol       Date:  1977 Sep-Oct       Impact factor: 6.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.